Immunovant, Inc.

Immunovant, Inc. financial statements

Immunovant, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

FY2026

RevenueUSD 0EODHD
Net income−USD 505.61M10-K
Cash and equivalentsUSD 902.11M10-Q
Total debtUSD 72KEODHD

Immunovant, Inc. financials on 6ix · Immunovant, Inc. on 6ix